PA-305 Mezigdomide, Carfilzomib, and Dexamethasone (MeziKd) vs Carfilzomib and Dexamethasone (Kd) in Relapsed/Refractory Multiple Myeloma (RRMM): Results From the Phase 3 SUCCESSOR-2 Trial
作者
Meletios Athanasios Dimopoulos,Fredrik Schjesvold,Chengcheng Fu,Monique A. Hartley-Brown,Cesar Augusto Gomez,Donna Ellen Reece,Gábor Mikala,Omar Alkharabsheh,Christopher Parrish,Darrell J. White,Hang Quach,Claudio Cerchione,Vânia Hungria,Amitabha Mazumder,Marc S. Raab,Albert Oriol,Zehua Zhou,Alberto Rocci,Brian Yu,Paul Gerard Guy Richardson